Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioCorRx (BICX) EBT Margin (2016 - 2025)

Historic EBT Margin for BioCorRx (BICX) over the last 15 years, with Q3 2025 value amounting to 127.28%.

  • BioCorRx's EBT Margin changed N/A to 127.28% in Q3 2025 from the same period last year, while for Sep 2025 it was 449.74%, marking a year-over-year increase of 181702600.0%. This contributed to the annual value of 67998.72% for FY2024, which is 637698200.0% down from last year.
  • As of Q3 2025, BioCorRx's EBT Margin stood at 127.28%.
  • In the past 5 years, BioCorRx's EBT Margin registered a high of 127.28% during Q3 2025, and its lowest value of 34184.06% during Q1 2024.
  • Moreover, its 5-year median value for EBT Margin was 5116.74% (2023), whereas its average is 8795.85%.
  • As far as peak fluctuations go, BioCorRx's EBT Margin plummeted by -316852100bps in 2024, and later surged by 335526500bps in 2025.
  • Quarter analysis of 5 years shows BioCorRx's EBT Margin stood at 9323.26% in 2021, then surged by 85bps to 1403.25% in 2022, then plummeted by -265bps to 5116.74% in 2023, then plummeted by -496bps to 30506.7% in 2024, then skyrocketed by 100bps to 127.28% in 2025.
  • Its EBT Margin stands at 127.28% for Q3 2025, versus 772.72% for Q2 2025 and 631.41% for Q1 2025.